FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523642232> ?p ?o ?g. }

• W2523642232 endingPage "118" @default.
• W2523642232 startingPage "106" @default.
• W2523642232 abstract "BackgroundPulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated.MethodsPatients were randomized to placebo, macitentan 3 mg, or macitentan 10 mg once daily. Patients aged 14 years or older completed the 36-Item Short Form Survey (SF-36) at baseline, at month 6 and month 12, and at the end of treatment (EOT). The absolute change from baseline to month 6 in SF-36 scores was calculated. The time to a clinically meaningful deterioration in the SF-36 physical component summary and mental component summary (PCS and MCS) scores and associations between baseline PCS/MCS scores and time to morbidity/mortality events were also assessed.ResultsAt month 6, macitentan 10 mg significantly improved seven of eight SF-36 domains and the PCS and MCS scores vs placebo. Macitentan 10 mg significantly reduced the risk of a three-point or greater deterioration in PCS (hazard ratio [HR], 0.60; 95% CI, 0.47-0.76; P < .0001) and MCS scores (HR, 0.76; 95% CI, 0.61-0.95; P = .0173) until EOT vs placebo. Patients with a baseline PCS score greater than the median baseline value had a significantly reduced risk of morbidity/mortality compared with patients with a PCS score less than the median; a similar result was observed for the MCS score.ConclusionsMacitentan significantly improved HRQoL in patients with PAH compared with placebo and significantly reduced the risk of a clinically meaningful HRQoL deterioration. An association between better baseline HRQoL and improved long-term outcomes was shown.Trial RegistryClinicalTrials.gov; No.: NCT00660179; URL: clinicaltrials.gov. Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated. Patients were randomized to placebo, macitentan 3 mg, or macitentan 10 mg once daily. Patients aged 14 years or older completed the 36-Item Short Form Survey (SF-36) at baseline, at month 6 and month 12, and at the end of treatment (EOT). The absolute change from baseline to month 6 in SF-36 scores was calculated. The time to a clinically meaningful deterioration in the SF-36 physical component summary and mental component summary (PCS and MCS) scores and associations between baseline PCS/MCS scores and time to morbidity/mortality events were also assessed. At month 6, macitentan 10 mg significantly improved seven of eight SF-36 domains and the PCS and MCS scores vs placebo. Macitentan 10 mg significantly reduced the risk of a three-point or greater deterioration in PCS (hazard ratio [HR], 0.60; 95% CI, 0.47-0.76; P < .0001) and MCS scores (HR, 0.76; 95% CI, 0.61-0.95; P = .0173) until EOT vs placebo. Patients with a baseline PCS score greater than the median baseline value had a significantly reduced risk of morbidity/mortality compared with patients with a PCS score less than the median; a similar result was observed for the MCS score. Macitentan significantly improved HRQoL in patients with PAH compared with placebo and significantly reduced the risk of a clinically meaningful HRQoL deterioration. An association between better baseline HRQoL and improved long-term outcomes was shown." @default.
• W2523642232 created "2016-09-30" @default.
• W2523642232 creator A5006434846 @default.
• W2523642232 creator A5007694037 @default.
• W2523642232 creator A5018526269 @default.
• W2523642232 creator A5025474536 @default.
• W2523642232 creator A5031477165 @default.
• W2523642232 creator A5045687304 @default.
• W2523642232 creator A5051583044 @default.
• W2523642232 creator A5065469571 @default.
• W2523642232 creator A5066741453 @default.
• W2523642232 creator A5068539599 @default.
• W2523642232 creator A5076930504 @default.
• W2523642232 creator A5077085879 @default.
• W2523642232 creator A5080797913 @default.
• W2523642232 creator A5083839456 @default.
• W2523642232 creator A5085067589 @default.
• W2523642232 creator A5090055088 @default.
• W2523642232 date "2017-01-01" @default.
• W2523642232 modified "2023-10-14" @default.
• W2523642232 title "Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension" @default.
• W2523642232 cites W1601872027 @default.
• W2523642232 cites W1964751504 @default.
• W2523642232 cites W1972203636 @default.
• W2523642232 cites W1989584416 @default.
• W2523642232 cites W2043978435 @default.
• W2523642232 cites W2055506823 @default.
• W2523642232 cites W2069323781 @default.
• W2523642232 cites W2071782474 @default.
• W2523642232 cites W2078822634 @default.
• W2523642232 cites W2096588893 @default.
• W2523642232 cites W2098700233 @default.
• W2523642232 cites W2103896976 @default.
• W2523642232 cites W2106484781 @default.
• W2523642232 cites W2107337478 @default.
• W2523642232 cites W2113473158 @default.
• W2523642232 cites W2153240795 @default.
• W2523642232 cites W2158575899 @default.
• W2523642232 cites W2158862125 @default.
• W2523642232 cites W2161370807 @default.
• W2523642232 cites W2165833527 @default.
• W2523642232 cites W2165838180 @default.
• W2523642232 cites W2332535725 @default.
• W2523642232 cites W2944404372 @default.
• W2523642232 cites W4241487982 @default.
• W2523642232 doi "https://doi.org/10.1016/j.chest.2016.08.1473" @default.
• W2523642232 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27671974" @default.
• W2523642232 hasPublicationYear "2017" @default.
• W2523642232 type Work @default.
• W2523642232 sameAs 2523642232 @default.
• W2523642232 citedByCount "45" @default.
• W2523642232 countsByYear W25236422322014 @default.
• W2523642232 countsByYear W25236422322015 @default.
• W2523642232 countsByYear W25236422322017 @default.
• W2523642232 countsByYear W25236422322018 @default.
• W2523642232 countsByYear W25236422322019 @default.
• W2523642232 countsByYear W25236422322020 @default.
• W2523642232 countsByYear W25236422322021 @default.
• W2523642232 countsByYear W25236422322022 @default.
• W2523642232 countsByYear W25236422322023 @default.
• W2523642232 crossrefType "journal-article" @default.
• W2523642232 hasAuthorship W2523642232A5006434846 @default.
• W2523642232 hasAuthorship W2523642232A5007694037 @default.
• W2523642232 hasAuthorship W2523642232A5018526269 @default.
• W2523642232 hasAuthorship W2523642232A5025474536 @default.
• W2523642232 hasAuthorship W2523642232A5031477165 @default.
• W2523642232 hasAuthorship W2523642232A5045687304 @default.
• W2523642232 hasAuthorship W2523642232A5051583044 @default.
• W2523642232 hasAuthorship W2523642232A5065469571 @default.
• W2523642232 hasAuthorship W2523642232A5066741453 @default.
• W2523642232 hasAuthorship W2523642232A5068539599 @default.
• W2523642232 hasAuthorship W2523642232A5076930504 @default.
• W2523642232 hasAuthorship W2523642232A5077085879 @default.
• W2523642232 hasAuthorship W2523642232A5080797913 @default.
• W2523642232 hasAuthorship W2523642232A5083839456 @default.
• W2523642232 hasAuthorship W2523642232A5085067589 @default.
• W2523642232 hasAuthorship W2523642232A5090055088 @default.
• W2523642232 hasBestOaLocation W25236422321 @default.
• W2523642232 hasConcept C126322002 @default.
• W2523642232 hasConcept C142724271 @default.
• W2523642232 hasConcept C144980905 @default.
• W2523642232 hasConcept C159110408 @default.
• W2523642232 hasConcept C164705383 @default.
• W2523642232 hasConcept C170493617 @default.
• W2523642232 hasConcept C204787440 @default.
• W2523642232 hasConcept C207103383 @default.
• W2523642232 hasConcept C27081682 @default.
• W2523642232 hasConcept C2776237627 @default.
• W2523642232 hasConcept C2776345702 @default.
• W2523642232 hasConcept C2779134260 @default.
• W2523642232 hasConcept C2779951463 @default.
• W2523642232 hasConcept C2780930700 @default.
• W2523642232 hasConcept C3019006561 @default.
• W2523642232 hasConcept C44249647 @default.
• W2523642232 hasConcept C71924100 @default.
• W2523642232 hasConceptScore W2523642232C126322002 @default.
• W2523642232 hasConceptScore W2523642232C142724271 @default.
• W2523642232 hasConceptScore W2523642232C144980905 @default.

• next